Floatz logo

gw786034

Clear Cell Metastatic Renal Cell Carcinoma

Association Pour La Recherche des Thérapeutiques Innovantes en CancérologiePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Clear Cell Metastatic Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Everolimus
Peking University First Hospital
Phase 2BB
Axitinib
University of California, San Francisco
Phase 3B
Nivolumab
Exelixis
Phase 2B
MODIFIED VACCINIA VIRUS ANKARA-5T4 ANTIGEN
Oxford BioMedica
Phase 3B
Toripalimab
RenJi Hospital
Phase 2B

View all 39 →

Same molecule, other indications

gw786034 is also rated in:

renal cell carcinomaDormant
BBB
Indicative ·
79 / 100
View asset →
nonpapillary renal cell carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
ovarian neoplasmDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →